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3LETTER TO THE EDITOR
ludarabine, Cyclophosphamide, and Antithymocyte
lobulin for a Patient with Dyskeratosis Congenita
nd Severe Bone Marrow Failure
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oDyskeratosis congenita (DC) is a rare inherited
one marrow failure syndrome characterized by a
lassic triad of abnormal skin pigmentation, nail dys-
rophy, and oral leukoplakia [1]. Two-thirds of deaths
n patients with DC are attributed to bone marrow
BM) failure [2]. Conventional hematopoietic stem
ell transplantation (SCT) is associated with an unex-
ectedly high frequency of early and late complica-
ions [3-6]. Although reduced-intensity conditioning
RIC) has been safely used in this setting, with durable
ngraftment and lower toxicity, there is no consensus
egarding the optimal conditioning regimen for this
isorder [3,7-11].
The European Group for Blood and Marrow
ransplantation (EBMT) has developed an RIC reg-
men for patients with severe aplastic anemia (SAA)
ho are not eligible for conventional conditioning
efore SCT [12]. Here we report the second case in
hich such a regimen was used before SCT in a
atient with DC and SAA [8]. We also review the
elevant literature on SCT and DC.
The patient was a 5-year-old girl, the fourth child
f a consanguineous couple. Pregnancy, delivery,
rowth, and development were all normal. The cou-
le’s second child, also a girl, had clinical features of
C and died of BM failure. The patient developed
eizures at age 1 month, but these were well controlled
y phenytoin. The nails of her hands and feet were
ystrophic at age 2 years, and 2 years later reticular
igmentation of the skin and intermittent oral leuko-
lakia appeared.
In June 2004, at age 5 years, the patient’s parents
ame in for consultation because of her easy bruising.
aboratory tests revealed a hemoglobin level of 7.8
/dL, hematocrit of 22%, a white blood cell count
f 2100/mm3 (neutrophils 609/mm3), and a platelet
ount of 16,000/mm3. BM aspiration and biopsy were
ompatible with SAA. The karyotype was normal, and
he diepoxybutane test was negative. Given the pa-
ient’s history of seizures, computed tomography (CT)
can of the head was obtained before BM transplan-
ation (BMT) and was found to be normal.In December 2004, the patient underwent BMT, c
66ith her healthy HLA-identical 17-year-old sister as
he donor. The EBMT RIC regimen was used [12]
fter approval by the institutional board and signed
nformed consent from the parents. The following
rugs and doses were given on days 6 to 3: ﬂu-
arabine (Flu) 30 mg/m2, cyclophosphamide (Cy) 300
g/m2 (40 mg/kg) and antithymocyte globulin (ATG)
.75 mg/kg (Thymoglobulin; Genzyme, Cambridge,
A). Unmanipulated BM was infused on day 0.
raft-versus-host disease (GVHD) prophylaxis con-
isted of mycophenolate mofetil (MMF) 15 mg/kg/day
nd cyclosporine A (CsA) 5 mg/kg/day, starting on
ay 2, for 6 and 12 months, respectively. The graft
ontained 2.06  108 mononuclear cells/kg. Engraft-
ent occurred on day 9 (984 neutrophils/mm3).
he posttransplantation course was uneventful, with
o signs of GVHD.
On posttransplantation days 30, 180, and 360,
ariable number of tandem repeats analysis on periph-
ral blood showed 100% donor chimerism of neutro-
hils and mononuclear cells. The patient was well 17
onths after the transplantation, with normal growth
nd development.
The only treatment option for DC patients with
AA has been allogeneic SCT; however, conventional
yeloablative conditioning regimens are associated
ith frequent and severe adverse events (eg, intersti-
ial pneumonia, lung ﬁbrosis, veno-occlusive disease,
econdary tumors) [3-6]. The optimal conditioning
egimen for these patients remains to be determined.
The chromosomal instability and inherited extreme
hort telomerase found in patients with DC is a possible
xplanation for their increased susceptibility to post-
ransplantation complications [13]. The EBMT RIC
egimen offers a high engraftment rate and low toxicity
n patients undergoing SCT for acquired and constitu-
ional SAA [12]. The case reported here suggests that
uch a regimen also may be used safely in patients with
C. The low-intensity dose is possibly less toxic to the
bnormal telomerase activity and telomerase shortening
bserved in patients with DC [1,4].
In this case, GVHD was successfully prevented by
ombining MMF and CsA. Moreover, the high dose
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Letter to the Editor 367f ATG given pretransplantation (a total dose of 15
g/kg) has been shown to be effective in preventing
cute GVHD [14,15]. The same conditioning regi-
en was used successfully in an 8-year-old boy with
C who underwent cord blood transplantation for
AA [8], with no early or late complications seen
uring 3 years of follow-up. GVHD prophylaxis con-
isted of CsA alone.
Including the present case, 30 patients with DC
ave now undergone SCT [1,3-11,16-22]. Nine of
hese patients received RIC [3,7-11,20], of whom 2
ied (22%) [3,20]. In contrast, the mortality rate in the
atients who underwent conventional transplantation
as 71% (15 of 21 patients who received conventional
yeloablative SCT died) [1,3-5,16-22]. Most of the
eaths were related to the SCT procedure. The 2
atients who died after RIC had received higher doses
f Cy (140 mg/kg and 60 mg/kg) than our patient (40
g/kg) [3,20]. Six patients, including our patient, have
eceived Flu-based regimens [8-10,20]; the only death
as of a patient who had received a higher dose of Cy
nd UD marrow, which per se carries a higher risk.
Compared with the RIC protocol followed here,
revious RIC regimens have used considerably
igher Cy doses [3], or a lower CsA dose but with
nother alkylating agent as an adjunct, such as
usulfan [7], or total body irradiation (TBI) (Table
) [9]. Although pulmonary complications have
een reported in DC patients with or without SCT,
t is advisable to avoid conditioning agents known to
e associated with pulmonary toxicity, such as
usulfan and irradiation [4].
Dror et al. [10] used a similar conditioning regi-
en for 2 patients with DC and severe marrow failure
ho underwent SCT with matched UDs. The regi-
en consisted of Flu 30 mg/m2/day from days 10 to
5, Cy 60 mg/kg/day on days 6 and 5, and equine
able 1. RIC for Patients in SAA with DC
ate Patient Sex
Age
(years)
SCT
Donor Conditioning
1996 1 M 33 MRD Cy-140, ATG C
2 M 22 MRD Cy-140, ATG a
1999 3 M 18 MRD Cy-80, Bus-0.8 G
4 F 21 MRD Cy-80, Bus-0.8 G
2002 5 M 8 MRD Cy-40, Flu-120, and
ATG
N
2003 6 F 10 MRD Flu-30, TBI-2 Gy N
7 M 3 MUD Flu-30, Cy-60, ATG N
8 F 8 MUD Flu-30, Cy-60, ATG N
2005 9 M 15 MUD Flu-30, Cy-60, ATG D
2005 10 M 5 MRD Cy-60, ATG N
2006 11 F 5 MRD Cy-40, Flu-120, ATG N
indicates female; M, male; MRD, matched related donor; MUD
Cause of death.hymocyte globulin 40 mg/kg/day from days 4 to1. Durable engraftment was achieved, and no early
r late severe adverse effects occurred. However, this
ame regimen was later administered to a boy with
C who also underwent UD BMT and died of an
arly complication (diffuse capillaritis). That regimen
ncluded a higher dose of Cy (60 mg/kg vs 40 mg/kg
n the present conditioning regimen). This illustrates
hat, despite early encouraging reports of some RIC
egimens, the ideal approach to patients with DC has
ot yet been identiﬁed, and modiﬁed SCT is war-
anted.
The transplantation regimen used here was well
olerated in our patient and in the previously reported
ase [8], both of which involved matched donors. This
egimen has also been safely used in patients with
cquired SAA who underwent SCT from mismatched
onors and UDs. The value of this regimen in patients
ith DC who have alternative donors remains to be
etermined.
Given the encouraging results, the high mortality
f the conventional regimen, and the lack of consensus
egarding the ideal conditioning regimen in patients
n SAA with DC, we believe that this protocol should
e explored further [23].
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